Rangeley Capital LLC Sells 26,000 Shares of Septerna, Inc. $SEPN

Rangeley Capital LLC cut its position in shares of Septerna, Inc. (NASDAQ:SEPN) by 39.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,800 shares of the company’s stock after selling 26,000 shares during the quarter. Rangeley Capital LLC owned about 0.09% of Septerna worth $956,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in Septerna in the first quarter valued at $906,000. Swiss National Bank acquired a new stake in Septerna during the 1st quarter worth about $531,000. Bank of New York Mellon Corp grew its holdings in Septerna by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after acquiring an additional 3,377 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Septerna in the 1st quarter worth about $619,000. Finally, Strs Ohio raised its position in shares of Septerna by 17.8% in the 1st quarter. Strs Ohio now owns 17,200 shares of the company’s stock worth $413,000 after acquiring an additional 2,600 shares in the last quarter.

Insider Buying and Selling

In related news, SVP Daniel D. Long sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,423,590.12. This represents a 13.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider owned 793 shares in the company, valued at approximately $23,837.58. The trade was a 93.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 44,494 shares of company stock worth $1,469,391. 5.80% of the stock is owned by company insiders.

Septerna Stock Performance

SEPN opened at $33.10 on Monday. The company has a fifty day moving average price of $32.91 and a two-hundred day moving average price of $28.30. Septerna, Inc. has a 1-year low of $10.62 and a 1-year high of $38.04. The company has a market cap of $1.49 billion, a P/E ratio of -40.86 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The company had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, research analysts forecast that Septerna, Inc. will post -1.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SEPN has been the topic of several research analyst reports. Raymond James Financial upped their target price on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a research report on Monday, June 8th. Stifel Nicolaus began coverage on Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Septerna in a research note on Wednesday, July 1st. Truist Financial increased their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Finally, Guggenheim reduced their price objective on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.89.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.